Compare AQST & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | BWAY |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.0M | 578.5M |
| IPO Year | 2007 | N/A |
| Metric | AQST | BWAY |
|---|---|---|
| Price | $4.18 | $14.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $9.00 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 1.5M | 107.6K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $10.08 | $309.69 |
| Revenue Next Year | $49.60 | $26.21 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.94 | $10.81 |
| 52 Week High | $7.55 | $26.63 |
| Indicator | AQST | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 53.52 | 43.12 |
| Support Level | $3.95 | $11.90 |
| Resistance Level | $4.38 | $14.65 |
| Average True Range (ATR) | 0.15 | 0.62 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 73.33 | 27.37 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.